Can intercalating chemotherapy with epidermal growth factor receptor inhibitors delay development of treatment resistance in advanced non-small cell lung cancer?

Expert Opin Pharmacother. 2017 Dec;18(18):1899-1902. doi: 10.1080/14656566.2017.1409721. Epub 2017 Nov 29.

Authors

Anna La Salvia^{1

2}, Emmanuele De Luca^{1

3}, Antonio Rossi⁴, Massimo Di Maio^{1

3}

Affiliations

¹ a Department of Oncology , University of Turin , Turin , Italy.
² b Division of Medical Oncology , "San Luigi Gonzaga" Hospital , Orbassano (TO) , Italy.
³ c Division of MedicalOncology , "Ordine Mauriziano" Hospital , Turin , Italy.
⁴ d OncologyDepartment , IRCSS Casa Sollievo della Sofferenza Hospital , San Giovanni Rotondo (FG) , Italy.

PMID: 29171767
DOI: 10.1080/14656566.2017.1409721

No abstract available

Keywords: Erlotinib; T790M; chemotherapy; epidermal growth factor receptor; gefitinib; intercalated; resistance.

Publication types

Editorial